Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04709965
Other study ID # R04765
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 30, 2018
Est. completion date November 25, 2020

Study information

Verified date January 2021
Source Manchester University NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Birth defects are relatively common, occurring in 1 in 40 live born babies. They can be single, or multiple. They may occur as part of multiple malformation syndromes, often in association with growth disturbance or intellectual disability. Over 7000 rare syndromes have been identified. Thus, though they are rare they are collectively important. Understanding how a multiple malformation syndrome came about, defining what investigations and health surveillance is needed for affected children and identifying whether there is a treatment is very important for parents and professionals caring for affected children and also for genetic counselling of their extended families, since the majority will have a genetic basis. Diagnosis of these rare disorders is therefore important,but as many syndromes are rare this can be extremely difficult and requires specialist knowledge, many investigations and many hospital appointments. This study aims to determine whether using face-recognition software can improve diagnosis of rare syndromes when used in addition to current routine practice.


Description:

Clinicians see over 2000 patients per year who have rare syndromes in Manchester NHS clinics. In the majority of these individuals the cause is unknown. Many will have a genetic cause, but knowing which genes to test and being able to access these tests is difficult. When a patient comes to the clinic, details of their medical and developmental history are collected , and they are examined in detail to look at their investigation results. New tests may also be ordered for patients. In many cases, subtle differences in physical features, especially facial features may provide an important clue to the underlying diagnosis. However, because many of the conditions seen are so rare and doctors may not have seen that particular condition before, the diagnosis may not be made immediately at the appointment. In those cases, permission will be sought to take photographs so that further opinions can be sought within the department or by sharing with national and sometimes international colleagues. This is routine practice. Where consent has been obtained for photos, these are then first reviewed in a departmental case-review meeting. They may then also be presented at regional, national or even international meetings aimed at syndrome diagnosis with patient consent. The study aims to recruit patients who are attending clinics for syndrome diagnosis, and who have differences in their facial features. Such patients will undergo a full routine diagnostic work-up as outlined above. Following that, if patients have consented to having photographs taken as part of standard care, they will be asked if they would consent to upload of the facial photographs to a digital face recognition system, along with upload of a list of key clinical features, to see which diagnoses are suggested by this software. A group of Inherited Metabolic Disease patients with known diagnoses will be included under the Faces sub-study to establish whether the technology may help to define their phenotype. This group of patients would be asked to send photos to the research team either by email via a secure email address or by post. The study would request one facial photo of each of the biological parents (where applicable and available). There will first of all be routine discussion of patients and photographs in a case review meeting as per standard practice. Differential diagnoses will be formulated and recorded based on this. Following this, the facial photo will be uploaded to a face recognition system and suggested diagnoses from this recorded. Any diagnostic suggestions considered worthy of investigation will be followed up in line with standard practice. The investigators will then determine whether this was made a) in the standard way b) only suggested by the face recognition software or c) utilising the two methods together. Patients will be followed up to see if a final diagnosis is confirmed. The patient/parents will also be sent a questionnaire by email or post 6 months after recruitment. The questionnaire will ask if they had any concerns about using FDNA, if they found it helpful and if so in what way. Another questionnaire to professionals will collect information on how easy they found it to use, how helpful they found it ranging 1-5, did it alter patient management, if so how, and other comments . The investigators will document whether utilising the software helped to arrive at an earlier diagnosis, whether it impeded the diagnosis by providing misleading or incorrect guidance, whether parents and professionals found its use acceptable and whether it impacted on the patient's management.


Recruitment information / eligibility

Status Completed
Enrollment 111
Est. completion date November 25, 2020
Est. primary completion date November 25, 2020
Accepts healthy volunteers No
Gender All
Age group 8 Months and older
Eligibility Inclusion Criteria: - Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern. OR: - Biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder Exclusion Criteria: - Patients under 8 months of age where face-recognition technology has not been shown to be effective. - Patients who decline clinical photography as part of standard care. - Patients who do not wish to consent to participation in the study even though they consent to photos being taken for standard care.

Study Design


Intervention

Diagnostic Test:
Face2Gene
This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.

Locations

Country Name City State
United Kingdom Manchester University NHS Foundation Trust Manchester Greater Manchester

Sponsors (2)

Lead Sponsor Collaborator
Manchester University NHS Foundation Trust FDNA Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of diagnoses The number of diagnoses of rare syndrome disorders made, measured after standard practice through study completion, an average of 2 years
Primary Number of diagnoses The number of diagnoses of rare syndrome disorders made, Measured after use of the Face2Gene app through study completion, an average of 2 years
Secondary Patient satisfaction Level of satisfaction of parents with use of a face recognition system and with e-health approaches to genetic counselling and diagnosis in general. Measured via a patient experiences questionnaire that requires both quantitative and qualitative responses. The proportion of patients who found use of the software acceptable will be measured. There results will not be reported on a fixed scale. 6 months after recruitment.
Secondary Professional satisfaction Level of satisfaction of professionals with use of a face recognition system. Measured via a colleagues experiences questionnaire that requires both quantitative and qualitative responses. The proportion of professionals who found using the software acceptable/helpful and would continue using the software in practice will be measured. There results will not be reported on a fixed scale. 24 months
Secondary Number of syndromes Number of syndromes identified where face recognition software has facilitated genetic investigation. 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Withdrawn NCT01003912 - Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Phase 1
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Recruiting NCT05818566 - Orphan Drugs for Inherited Metabolic Diseases
Completed NCT05330039 - Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Completed NCT03911089 - A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD N/A
Completed NCT03058848 - Evaluation of PKU Start N/A
Suspended NCT04399694 - Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
Terminated NCT00654433 - ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Phase 3
Completed NCT03168399 - Evaluation of PKU Explore N/A
Recruiting NCT00078078 - Clinical and Laboratory Study of Methylmalonic Acidemia
Completed NCT00328159 - Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids N/A
Completed NCT04309331 - Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute N/A
Recruiting NCT06360913 - Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases N/A
Completed NCT00309400 - The Early History of Universal Screening for Metabolic Disorders N/A
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A